PFE · 8-K · 20260804PR000094

Restructuring Charges

PFIZER INC · 2026-08-04 · Importance 59 · Surprise 82

Second-quarter 2026 restructuring charges, implementation costs and additional depreciation related to asset restructuring totaled $91 million, compared with $29 million in the second quarter of 2025. Six-month 2026 restructuring-related charges totaled $91 million, compared with $53 million in the prior-year period. The charges include employee termination costs, asset impairments and other exit costs associated with Pfizer’s cost-reduction and productivity initiatives. The six-month reconciliation also included $670 million of other significant items, primarily reflecting non-restructuring adjustments.

Key facts

• Second-quarter 2026 restructuring charges and certain acquisition-related costs: $457 million source
• Second-quarter 2026 components of restructuring charges included $391 million charges for cost reduction initiatives (primarily employee termination costs associated with enterprise-wide cost realignment program) source